Growth Metrics

Heron Therapeutics (HRTX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $615000.0.

  • Heron Therapeutics' Depreciation & Amortization (CF) rose 585.2% to $615000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 993.53%. This contributed to the annual value of $2.5 million for FY2024, which is 1379.31% down from last year.
  • Per Heron Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $615000.0 for Q3 2025, which was up 585.2% from $611000.0 recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Depreciation & Amortization (CF) peaked at $794000.0 during Q4 2021, and registered a low of $551000.0 during Q1 2025.
  • In the last 5 years, Heron Therapeutics' Depreciation & Amortization (CF) had a median value of $716000.0 in 2023 and averaged $688789.5.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 1900.16% in 2021, then tumbled by 2008.25% in 2024.
  • Quarter analysis of 5 years shows Heron Therapeutics' Depreciation & Amortization (CF) stood at $794000.0 in 2021, then dropped by 0.38% to $791000.0 in 2022, then dropped by 9.48% to $716000.0 in 2023, then decreased by 17.74% to $589000.0 in 2024, then rose by 4.41% to $615000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $615000.0 for Q3 2025, versus $611000.0 for Q2 2025 and $551000.0 for Q1 2025.